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Abstract 
In the present study, asymmetric membrane capsules (AMCs) with two com-
partments were successfully developed for simultaneous delivery of two poorly 
water-soluble drugs, Atenolol and Amlodipine Besylate, by using solubility 
modulation approach. Scanning electron microscopy (SEM) before dissolution 
showed presence of outer dense region and inner porous region for the 
prepared asymmetric membrane and the pore size increased after dissolution 
for both outer and inner layer. Diffuse reflectance spectroscopy (DRS) showed 
no incompatibility between the drug(s) and the excipients used in the study. The 
developed system was able to control the release of ATN and AMB by 
increasing the solubility through buffering agents of different strengths (0.25N to 
1.0N). As the level of buffering agent was increased, the solubility of drugs also 
increased inside the asymmetric membrane capsule. The developed system 
was independent of the agitation intensity of the dissolution fluid but was 
dependent on the polymer diffusibility and osmotic pressure of the media, which 
clearly stated that osmotic pumping was the primary mechanism of drug(s) 
release from AMCs. The results of in-vitro demonstration of effect of membrane 
thickness on dissolution fluid entering AMCs showed that as the membrane 
thickness increased the volume of dissolution fluid entering into AMC 
decreased.  The release kinetic studies of different formulations of AMCs 230  S. Garg et al.:   
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showed  that formulation code six, which consists of the highest amount of 
osmotic agents and optimum amount of buffering agents, was the best 
formulation, and it followed zero order release kinetics (r
2=0.9990 for ATN and 
r
2=0.9988 for AMB).  
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Introduction  
Development of osmotically regulated multi-drug oral delivery system would have the 
possibility of simultaneous administration of two or more drugs for the treatment of chronic 
diseases such as hypertension. The system would provide simultaneous delivery of two or 
more drugs, which is required to reduce the problems associated with multi-drug therapy. 
In addition, the system may provide the release of drugs in a near zero order rate, which is 
an ideal release profile for controlled drug delivery that in turn would improve safety profile 
of the drugs and enhancement of activity duration for drugs exhibiting short half life. And, 
once-daily formulations (optimized therapy) would increase the improved patient 
compliance [1]. 
The asymmetric membrane capsule is a controlled drug delivery device which consists of 
a drug-containing core surrounded by a membrane which has an asymmetric structure, 
i.e., it has a relatively thin, dense region supported on a thicker, porous region. Similar to a 
conventional telescoping hard gelatin capsule, the asymmetric membrane capsule 
consists of a cap and a body that snugly fit into each other. The cap is shorter in length 
and has a slightly larger diameter than the body which is longer and has a smaller 
diameter.  
Drug delivery from asymmetric membrane dosage forms is primarily controlled by the 
difference in osmotic pressure between the external fluid and drug-containing core of the 
dosage form. The mechanism of drug release from an AM capsule consists of imbibitions 
of water through the membrane into the tablet core, dissolution of soluble components 
(including drug) in the core and pumping of the solution out of pores in the membrane. The 
imbibitions of water through the membrane are driven by its thermodynamic activity gradi-
ent between the external medium, e.g., receptor solution or gastric / intestinal fluids, and 
the osmotic agent in the core. Dissolution of the soluble components within the core 
produces the activity gradient and establishes the osmotic pressure difference between 
the core and external environment. 
As water diffuses into the core, the volume of the imbibed water creates a hydrostatic 
pressure difference across the membrane, which forces the solution out through the pores 
in the coating. Therefore, the rate of drug delivery will be constant as long as a constant 
osmotic pressure gradient is maintained across the membrane, the membrane 
permeability remains constant, and, the concentration of drug in the expelled solution is 
constant [2, 3].  
Atenolol is a β-adrenergic receptor blocking agent without membrane stabilizing or intrinsic 
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combination is used for the treatment of hypertension. It is reported that in case of atenolol 
oral administration, the tablet is usually administered two or three  times a day, which 
would lead to large fluctuation in drug plasma concentration and side effects like diarrhea, 
nausea, ischemic colitis and mesenteric arterial thrombosis on human body. Amlodipine 
Besylate is extensively metabolized by liver to inactive metabolites. Steady-state plasma 
levels of amlodipine besylate are reached after 7 to 8 days of consecutive daily dosing. 
This combination is commercially available as a conventional tablet. Both drugs have poor 
aqueous solubility, which would lead to large fluctuation in drug plasma concentration. 
Controlled release systems are highly desirable to solve these problems [4–6].  
Therefore, the aim of this work was (1) to develop two-compartment asymmetric 
membrane capsules (AMC) for simultaneous controlled release of atenolol and amlodipine 
besylate and study the release of drugs from these formulations and (2) to evaluate the 
effect of membrane thickness on dissolution fluid entering the AMC and (3) to evaluate the 
effect of different osmotic pressure conditions, agitation intensity and polymer diffusibility 
on drug release from the prepared AMCs. 
Experimental 
Materials  
Atenolol (ATN) was obtained as gift samples from IPCA Lab. Ltd., Ratlam, India and 
amlodipine besylate (AMB) was obtained as gift samples from Cadila pharmaceuticals, 
Ahmedabad, India. Sodium hydroxide, acetone, methanol and potassium chloride were 
procured from Qualigens Pvt. Ltd., Mumbai, India. Ehanol and potassium dihydrogen 
phosphate were procured from S.D. fine chemicals, Mumbai, India. Cellulose acetate, 
sorbitol 70% and citric acid monohydrate were procured from Fluka, U.K., Central drug 
house Ltd., New Delhi, India and Ranbaxy fine chemicals, New Delhi, India, respectively. 
All other chemicals used in study were of analytical grade. 
Methods 
Drug-drug and drug-excipient(s) compatibility study 
Drug-drug and drug-excipient(s) compatibility were carried out using diffuse reflectance 
spectroscopy (DRS). In this technique solid drug, excipient(s) and their physical mixtures 
were diluted with KBr (IR grade) to get the samples for measurement in the transmittance 
mode (%T). The diffuse reflectance spectrum of the samples against the diluting material 
was measured by setting the accumulation time to approximately 50. The spectra obtained 
were evaluated for any incompatibility.  
Preparation of asymmetric membrane capsules (AMCs) of atenolol and amlodipine 
besylate 
AMCs were produced by using a dip coating (wet phase inversion) process. The glass 
mold pins were dipped into polymer solution consisting of cellulose acetate (10 %w/v or 
15%w/v) dissolved in a mixture of acetone, alcohol and sorbitol, followed by quenching in 
a 10% v/v aqueous solution of sorbitol for 10 min. After quenching,  the pins were 
withdrawn and allowed to air dry. Then, the capsules were stripped off the pins, trimmed to 
size and kept into dessicator until use [3]. 232  S. Garg et al.:   
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Formation of compartment, filling and sealing of AMCs 
The physical mixture of Atenolol (50 mg) and osmotic agent KCl (25, 50 and 100 mg) and 
citric acid monohydrate (17.5 mg) were prepared by mixing them in polyethylene bag for at 
least 10 min and filled inside the capsule’s body, the physical mixture of Amlodipine 
Besylate (5 mg) and osmotic agent, KCl (5, 10 and 20 mg) and citric acid monohydrate 
(35 mg) were also prepared by mixing them in polyethylene bag for at least 10 min, and 
filled inside the capsule’s cap manually. Compartments were formed using paraffin wax 
plug (due to its inertness), and a layer of cellulose acetate solution (10% w/v) was applied 
over it to ensure non-  leakage of drug solution from cap and body. After the filling 
operation, the capsules were capped and sealed with a sealing solution (10% w/v cellulose 
acetate in a mixture of acetone and alcohol).  
Tab. 1.  Formulation design of AMCs for simultaneous release of atenolol and 
amlodipine besylate 
No.  COMPONENT  AMOUNT (mg) 
F1  F2  F3  F4  F5  F6 
C  B  C  B  C  B  C  B  C  B  C  B 
1.  Atenolol  –  50  –  50  –  50  –  50  –  50  –  50 
2.  Amlodipine 
Besylate  5  –  5  –  5  –  5  –  5  –  5  – 
3.  Potassium 
chloride  –  –  –  –  10  50  10  50  5  25  20  100 
4.  Citric acid 
monohydrate  –  –  35  17.5  –  –  35  17.5  35  17.5  35  17.5 
C…Cap; B…Body. 
 
Characterization of AMCS of atenolol and amlodipine besylate 
Appearance and dimension 
The asymmetric membrane capsules were characterized for appearance and dimension. 
AMCs were compared visually with regard to transparency and opacity. Dimensions of 
AMCs were determined by using a vernier caliper. A multiple of three determinants was 
used for measurement of each dimension. The results of the studies were statistically 
compared with conventional hard gelatin capsules at P<0.05. 
Scanning electron microscopy 
Asymmetric membrane before and after completion of dissolution of core was examined 
for their porous structure and thickness using Leo 435 VF scanning electron microscope 
(SEM). After dissolution, asymmetric membrane structure was dried at 50°C for 8 hrs and 
stored in dessicator before examination. The asymmetric membrane was sputter coated 
for 5–10 min with gold by using fine coat ion sputter and examined under SEM. 
In-vitro release studies 
In vitro percent cumulative drug release from prepared formulations were studied by using 
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37±0.5 °C. The release media was 0.1 N HCl (pH 1.2) as simulated gastric fluid (SGF pH 
1.2, 750 ml) for the first 2 h, followed by phosphate buffer as simulated intestinal fluid (SIF 
pH 7.4, 900 ml) for rest of experiment. Five ml of the sample was withdrawn at specified 
time intervals, and suitably diluted with fresh release media and analyzed at the drug(s) 
their respective λmax 276 nm for Atenolole and 360 nm for Amlodipine wavelengths. The 
amount of cumulative percent released at each time point was calculated. 
Kinetics of in-vitro release 
In general the release of drug from an osmotic system depends on many factors such as 
osmotic pressure, pore size and coating thickness. The in vitro release from F1 formulation 
containing only drugs (50 mg atenolol and 5 mg amlodipine besylate, without the KBr and 
citric acid monohydrate) exhibited a limited drug release because of erratic dissolution 
profile at gastric pH therefore limited bioavailability 50–60% [7].  The release from the 
formulations containing osmotic agents and buffering agents was more controlled, with 
increased bioavailability 80–85%.  The zero-order rate describes systems where drug 
release is independent of its concentration and is generally seen for poorly water-soluble 
drug in matrix, transdermals, etc [8].  
Eq. 1.   Qt = k0t 
The first-order describes systems in which the release is dependent on its concentration 
(generally seen for water-soluble drugs in porous matrix) [9].  
Eq. 2.   ln Qt = ln Q0 − k1t 
The Higuchi model describes the release of the drug from an insoluble matrix to be linearly 
related to the square root of time and is based on Fickian diffusion.  
Eq. 3.   Qt = kHt
1/2 
The Hixson-Crowell cube root law describes the release of drug from systems where it 
depends on the change in surface area and diameter of the particles or tablets with time 
and mainly applies in the case of systems that dissolute or erodes over time.  
Eq. 4.   Q0
1/3 – Qt
1/3 = kHCt 
Where Qt is the amount of drug released at time t, Q0 is the initial amount of the drug in the 
formulation, k0, k1, kH and kHC are release rate constants for zero order, first order, Higuchi 
model and Hixson-Crowell rate equations. 
Effect of variables on drug release 
Effect of osmotic pressure on drug release 
Osmotic pressure and effect of the osmotic agent inside the formulation plays a vital role in 
deciding the release of drug from asymmetric membrane capsules. To  confirm the 
mechanism of drugs release, release studies of the optimized formulation were conducted 
in media of different osmotic pressure  (11.08 mmHg, 27.68 mmHg, 55.32 mmHg and 
110.64 mmHg).  The reason for the selection of these osmotic pressures was to have 
hyper and hypo osmotic conditions, and study them in comparison to the selected 234  S. Garg et al.:   
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asymmetric membrane capsules. This was to justify that osmotic pressure was the reason 
behind the drug release from these formulations. 
To increase the osmotic pressure of the dissolution medium (SIF), potassium chloride 
(osmotically active solute) was added, and the pH was adjusted to 7.4±0.5. Release 
studies were performed in 900 ml of media using USP-2 (paddle type) dissolution 
apparatus (100 rpm). Five ml of the sample was withdrawn at specified time intervals and 
suitably diluted with fresh release media and analyzed at respective wavelengths to 
determine the amount of Atenolol and Amlodipine Besylate releases from each AMC [2]. 
Effect of agitation intensity 
Release studies were carried out at three different speeds namely 50, 100 and 150 rpm 
using USP-2 apparatus at 37±0.5 °C, and their effects on release profile were studied by 
analyzing the amount of drugs released from the formulation at predetermined intervals at 
respective wavelengths and then comparing the profile by using one-way ANOVA [10]. 
Effect of polymer diffusibility 
The diffusibility of drug molecules through the rate-controlling membrane of a polymer 
membrane permeation controlled drug delivery system from the optimized formulation was 
studied using both the formulation stored in a dessicator for 24 h and also that from a 
freshly fabricated drug delivery system device. In-vitro dissolution for 1 h was done with a 
sampling time of 10 min. One milliliter of the sample was withdrawn and suitably diluted 
and analyzed at respective wavelength. The effect of polymer diffusibility was calculated 
using equation 5 for AMCs that were freshly fabricated and equation 6 for those stored for 
24 h. 
Eq. 5.   Dp = Hp
2/6tl 
Where Dp is the polymer diffusibility, Hp is the thickness of the polymer membrane, and tl is 
the time axis intercept of the back extrapolation through the steady-state drug release 
data. 
Eq. 6.   Dp = Hp
2/3tb 
Where Dp is the polymer diffusibility, Hp is the thickness of the polymer membrane, and tb 
is the negative time axis intercept of the back extrapolation through the steady-state drug 
release data [11]. 
In-vitro demonstration of effect of membrane thickness on dissolution fluid entering 
the AMC 
To demonstrate the effect of membrane thickness on dissolution fluid entering the AMC, 
the volume that enters in the capsules was determined. For the determination of volume, 
different osmotic pressures were created in the external media by adding different 
amounts of osmotic agent. It was assumed that when the osmotic pressure inside the 
capsule and external media was equal (i.e. iso-osmotic) there will be no release of drugs. 
The osmotic pressure of media, at which the release was zero, was determined and by the 
use of this osmotic pressure volume of dissolution fluid that entered into the AMC can be 
calculated by using following equation.   Osmotically Regulated Two-Compartment Asymmetric Membrane Capsules for Simultaneous …  235 
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Eq. 7.   πV = nRT 
Where π is the osmotic pressure in atm, V is the volume of solution in liters, n is the 
number of moles of solute, R is the gas constant equal to 0.082 liter atm/mole deg, and T 
is the absolute temperature [12].  
Stability studies 
Stability studies were carried out as per ICH Q1A stability guidelines. The formulated 
capsules were subjected to 40 °C±2.0 °C / 75% RH±5% for 3 months, and the samples 
were evaluated for physical parameter and in vitro release by UV spectrophotometer at 
respective wavelengths. The sampling intervals were 0,1,2,3 months. 
Results and discussion 
Drug-Drug and drug-excipients compatibility studies 
The physical mixture of drug and excipient(s) did not show any physical incompatibility in 
terms of discoloration, caking and liquefaction. The presence of excipient(s) did not result 
in any shift in the DRS of the drug(s) nor did it show the appearance of new peak (Fig. 1 to 
Fig. 5). DRS spectra of mixture of ATN and AMB along with polymers retained all the 
characteristic peaks of ATN and AMB and showed no incompatibility. Hence it can be 
concluded that AMCs prepared by cellulose acetate, KCl and citric acid monohydrate are 
stable in terms of physical and chemical stability.  
 
Fig. 1.  DRS spectra of (a) ATN, (b) AMB and (c) mixture of ATN and AMB 236  S. Garg et al.:   
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Fig. 2.   DRS spectra of (a) mixture of ATN and AMB, (b) cellulose acetate and (c) 
mixture of ATN, AMB and cellulose acetate 
 
Fig. 3.  DRS spectra of (a) mixture of ATN and AMB, (b) citric acid monohydrate and (c) 
mixture of ATN, AMB and citric acid monohydrate   Osmotically Regulated Two-Compartment Asymmetric Membrane Capsules for Simultaneous …  237 
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Fig. 4.  DRS spectra of (a) mixture of ATN and AMB, (b) KCl and (c) mixture of ATN, 
AMB and KCl 
 
Fig. 5.  DRS spectra of (a) mixture of ATN and AMB, (b) KCl, (c) cellulose acetate, (d) 
citric acid monohydrate and mixture of ATN, AMB, KCl, CA and citric acid 
monohydrate 238  S. Garg et al.:   
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Characterization and evaluation of prepared capsules 
The appearance and dimensions of asymmetric membrane capsules were studied. The 
appearance and dimensions of the AMCs were compared to conventional hard gelatin 
capsules (Table 2). AMCs were found to possess high opacity as compared to the 
conventional capsules. Comparison of the dimensions of the capsules showed that there is 
a high degree of similarity (P= 0.0012) in physical appearance between the conventional 
hard gelatin capsules (HGCs) and AMCs. 
Tab. 2.  Physical characterization of AMC as compared to HGC 
Type  Opaque  Size 
Cap  Body  Sealed 
(mm)  L (mm)  D (mm)  L (mm)  D (mm) 
HGC  +  10.12±0.11  7.85±0.12  18.02±0.13  7.02±0.12  21.85±0.11 
AMC  ++  10.21±0.14  7.95±0.13  18.23±0.14  8.12±0.13  22.43±0.23 
 
Scanning electron microscopy (SEM) 
The photographs revealed the typical characteristics of asymmetric membrane with outer 
dense region and inner porous region (Fig. 6 A and Fig. 6 B). The original concept was to 
form an asymmetric membrane film consisting of a  thick porous region to provide 
mechanical support and a thin dense region to provide perm selectivity. Scanning 
micrograph of asymmetric membrane confirmed that the asymmetric nature of the 
membrane is a function of plasticizer. The process followed for manufacturing of AMCs in 
lab was reproducible and produced asymmetric membranes structurally similar to the ones 
recorded in literature for osmotic drug delivery. 
In-vitro dissolution studies 
The in-vitro dissolution studies were carried out in 0.1N HCl (pH 1.2) for the initial 2 h, and 
then followed by phosphate buffer (pH 7.4) for rest of time. The results of dissolution 
studied were compared by one-way ANOVA which was followed by Dunnett’s multiple 
comparison test in which each formulation was compared with a control formulation (F1) to 
test whether there was significant difference between different formulations compared to 
control formulation (F1). The result of ANOVA showed that Fcal value (5.296 for ATN and 
7.15 for AMB) was more than Ftab value (2.34 for ATN and 2.39 for AMB) which was 
statistically significant at 95% confidence interval between the all six formulations. Then 
Dunnett’s multiple comparison test was applied to identify which formulation was different 
from control formulation (F1).  
The result of Dunnett’s multiple comparison test showed that when F2 formulation, (which 
consisted of pure drugs and buffering agent) was compared with F1 formulation, which 
consisted  of only pure drugs only, both dissolution profiles had statistically significant 
difference (q>2.574 & P<0.01) for both the drugs. F1  formulation showed less % 
cumulative release than F2 formulation, because both drugs were poorly water soluble so 
were unable to solubilize in dissolution media but by the incorporation of buffering agent 
solubility was increased, as in F2  formulation so % cumulative release was high in F2 
formulation.    Osmotically Regulated Two-Compartment Asymmetric Membrane Capsules for Simultaneous …  239 
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A  B 
   
C  D 
Fig. 6.  SEM of asymmetric membrane (A) outer dense membrane (B) inner porous 
region before dissolution and (C) outer dense region (D) inner porous region 
after complete dissolution, 10% w/w sorbitol 
When F3 formulation, which consisted of osmotic agent (KCl) along with pure drugs, was 
compared with F1  formulation both dissolution profiles had statistically insignificant 
difference (q<2.574 & P>0.05) for both drugs. F3  formulation showed slightly high % 
cumulative release than F1 formulation (Table 3, and Fig. 7., Fig. 8), because drug release 
due to solubility of drugs, but there maybe little contribution of the osmotic effect of osmotic 
agent for the drug that was solubilized in dissolution media. 
When F5, F4  and F6  formulation, which consisted  of low, medium and high amount of 
osmotic agent respectively and same amount of buffering agent along with pure drugs, 240  S. Garg et al.:   
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were compared with F1 formulation individually, they were statistically significantly different 
(q>2.574 & P<0.01) from control formulation (F1) for both drugs. All three formulations (F4, 
F5 and F6) showed higher % cumulative release than F1 formulation (Table 3) due to the 
combined effect of both osmotic agent and buffering agent. Among the all three 
formulations (F4, F5  and F6),  F6  formulation showed maximum % cumulative release 
because as the amount of osmotic agent increased, the % cumulative release also 
increased and release became more controlled.  
Tab. 3.  In-vitro release data of different formulations of ATN and AMB 
Time 
(hr) 
% Cumulative drug release 
F1  F2  F3  F4  F5  F6 
ATN  AMB  ATN  AMB  ATN  AMB  ATN  AMB  ATN  AMB  ATN  AMB 
0  0  0  0  0  0  0  0  0  0  0  0  0 
1  3.67 
±0.24 
2.91 
±0.16 
6.23 
±0.16 
10.54 
±0.54 
5.77 
±0.23 
3.26 
±0.21 
8.72 
±0.21 
18.72 
±0.27 
6.76 
±0.22 
15.25 
±0.37 
11.82
±0.45 
20.58
±0.35 
2  5.13 
±0.21 
4.11 
±0.14 
12.45 
±0.29 
24.47 
±0.47 
8.79 
±0.36 
5.32 
±0.32 
16.11
±0.35 
35.69 
±0.36 
12.69
±0.66 
30.39 
±0.41 
20.56
±0.63 
36.58
±0.54 
3  8.78 
±0.32 
6.63 
±0.24 
17.83 
±0.43 
41.58 
±0.25 
11.68
±0.47 
7.19 
±0.25 
22.98
±0.57 
53.56 
±0.57 
18.38
±0.75 
48.55 
±0.29 
28.29
±0.13 
58.42
±0.53 
4  11.47
±0.55 
7.24 
±0.26 
24.83 
±0.36 
55.69 
±0.36 
14.59
±0.46 
9.15 
±0.34 
29.29
±0.75 
77.65 
±0.76 
25.39
±0.45 
71.55 
±0.54 
37.45
±0.24 
82.93
±0.23 
5  13.98
±0.47 
9.21 
±0.17 
33.49 
±0.67 
77.65 
±0.46 
17.28
±0.65 
11.41
±0.53 
39.44
±0.37 
88.52 
±0.74 
32.88
±0.31 
86.25 
±0.37 
47.35
±0.34 
98.52
±0.19 
6  15.76
±0.76 
11.53
±0.13 
39.47 
±0.46 
87.29 
±0.32 
19.26
±0.67 
13.92
±0.52 
44.29
±0.53 
96.63 
±1.16 
37.62
±0.31 
94.37 
±0.43 
54.62
±0.43 
100 
±0.02 
7  19.69
±0.88 
12.21
±0.28 
41.45 
±0.64 
93.45 
±0.43 
22.59
±0.65 
15.64
±0.54 
52.44
±0.45 
100 
±0.13 
41.23
±0.47 
100 
±0.04 
60.76
±0.84   
8  22.43
±0.56 
13.59
±0.32 
45.76 
±0.76 
100 
±0.08 
24.62
±0.38 
16.83
±0.37 
59.63
±0.63   
46.33
±0.56   
68.81
±0.75   
9  24.45
±0.91 
15.25
±0.24 
49.85 
±0.78   
27.75
±0.54 
17.87
±0.74 
65.87
±0.47   
51.58
±0.74   
74.73
±0.56   
10  26.44
±0.45 
16.68
±0.43 
51.52 
±0.56   
30.92
±0.37 
19.92
±0.62 
71.92
±0.39   
54.69
±0.47   
79.83
±0.57   
11  29.75
±0.75 
19.29
±0.37 
53.69 
±0.75   
34.29
±0.67 
22.26
±0.57 
78.68
±0.78   
58.73
±0.73   
86.58
±0.53   
12  32.98
±1.24 
20.75
±0.23 
55.37 
±0.64   
36.5±
0.78 
24.59
±0.51 
84.29
±0.87   
64.46
±0.57   
91.76
±0.54   
 
Modification of best formulation (F6) 
The best formulation (F6) was modified because this formulation was not able to deliver 
Amlodipine Besylate up to 12 h, although it was delivering Atenolol up to 12 h. So the cap 
of the AMC was prepared with 15% w/v coating solution (cellulose acetate solution in 
acetone and alcohol) and the composition of body, which consisted of Atenolol, remained 
unchanged (i.e. 10% w/v cellulose acetate solution in acetone and alcohol). The result 
showed that after modification the formulation (F6) was able to deliver Amlodipine Besylate 
up to 12 h (Table 4 & Fig. 9).   Osmotically Regulated Two-Compartment Asymmetric Membrane Capsules for Simultaneous …  241 
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Fig. 7.  In-vitro drug release profiles of Atenolol in dissolution media 
 
 
 
Fig. 8.  In-vitro drug release profiles of Amlodipine Besylate in dissolution media 
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Tab. 4.  In-vitro drug release data of modified formulation (F’6) 
S.No.  Time  
(hrs) 
% Cumulative drug release 
Atenolol  Amlodipine  
Besylate 
1.  0  0  0 
2.  1  10.73±0.134  11.23±0.546 
3.  2  19.68±0.154  22.76±0.647 
4.  3  24.68±0.163  30.86±0.748 
5.  4  32.56±1.420  40.75±0.843 
6.  5  42.82±0.876  48.57±0.832 
7.  6  47.76±0.433  55.57±0.174 
8.  7  56.89±0.731  63.29±0.738 
9.  8  63.92±0.674  71.52±0.736 
10.  9  69.83±0.763  77.73±0.236 
11.  10  76.83±0.772  82.73±1.312 
12.  11  83.58±0.883  88.82±1.523 
13.  12  89.63±0.912  94.69±0.646 
 
 
Fig. 9.  In-Vitro drug release profile of modified F6 formulation 
Kinetics of drug release 
All the models for selecting the release profile were applied on all the AMC formulations 
(F1 to modified best formulation F’6). The results are summarized in Tabele 5. Results 
showed that best fit model in all the cases except F2 could have followed the Zero order, 
first order, Matrix model and the Peppas model. While considering higher correlation 
coefficient value (r
2), the release data seems to fit Zero- order model better. According to 
correlation coefficient value (r
2) of release models F6 seems to be the best formulation.   Osmotically Regulated Two-Compartment Asymmetric Membrane Capsules for Simultaneous …  243 
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Tab. 5.  Different kinetic models applied on AMMC formulations 
KINETIC  
MODEL 
FORMULATION 
F1  F2  F3  F4 
ATN  AMB  ATN  AMB  ATN  AMB  ATN  AMB 
Zero order (r
2)  0.9867  0.9798  0.8979  0.8897  0.9944  0.9956  0.9980  0.9978 
First order (r
2)  0.9557  0.9628  0.9913  0.9924  0.9244  0.9239  0.8986  0.9014 
Higuchi (r
2)  0.9322  0.9230  0.8956  0.7857  0.9678  0.9668  0.9797  0.9762 
Peppas (r
2)  0.9719  0.9669  0.7845  0.7699  0.9953  0.9961  0.9962  0.9975 
KINETIC  
MODEL 
FORMULATION     
F5  F6  F’6     
ATN  AMB  ATN  AMB  ATN  AMB     
Zero order (r
2)  0.9979  0.9973  0.9990  0.9988  0.9985  0.9973     
First order (r
2)  0.8494  0.8776  0.8874  0.8644  0.8874  0.9632     
Higuchi (r
2)  0.9927  0.9841  0.9791  0.9792  0.9543  0.9543     
Peppas (r
2)  0.9934  0.9943  0.9937  0.9938  0.9949  0.9970     
 
Effect of variables on drug release 
Effect of osmotic pressure on drug release 
The result of release studies in media of different osmotic pressure showed that the in vitro 
release of ATN and AMB is highly dependent on the osmotic pressure of the release 
media (Table 6). Drug release from the formulation decreased as the osmotic pressure of 
the media increased (Fig. 10 & 11). On plotting graph between external osmotic pressure 
and release rate, the release rate decreases linearly with increase in external osmotic 
pressure (Fig. 12). It was concluded that osmotic pumping is the major mechanism 
governing the release from developed formulation [2].  
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Tab. 6.  Effect of varying external osmotic pressure on in-vitro release 
Time 
(hr) 
% Cumulative drug release 
0 mmHg  11.08 mmHg  27.68 mmHg  55.32 mmHg  110.64 mmHg 
ATN  AMB  ATN  AMB  ATN  AMB  ATN  AMB  ATN  AMB 
0  0  0  0  0  0  0  0  0  0  0 
1  11.82 
±0.23 
20.58 
±0.33 
8.52 
±0.13 
13.76 
±0.19 
6.39 
±0.62 
10.37 
±0.77 
4.32 
±0.21 
8.35 
±0.13 
2.78 
±0.43 
4.25 
±0.11 
2  20.56 
±0.32 
36.58 
±0.54 
17.28 
±0.32 
27.29 
±0.76 
12.53 
±0.43 
22.45 
±0.98 
8.57 
±0.23 
15.27 
±0.77 
5.81 
±0.25 
8.38 
±0.16 
3  28.29 
±0.45 
58.42 
±0.11 
20.63 
±0.59 
44.39 
±0.59 
16.12 
±0.53 
34.25 
±1.09 
13.56 
±0.66 
22.35 
±0.63 
8.63 
±0.53 
13.42 
±0.34 
4  37.45 
±0.22 
82.93 
±0.55 
26.43 
±0.52 
60.29 
±0.24 
21.39 
±0.53 
48.57 
±0.65 
16.76 
±0.42 
32.56 
±0.52 
12.76 
±0.88 
19.62 
±0.55 
5  47.35 
±0.25 
98.52 
±0.32 
36.58 
±0.66 
76.62 
±0.22 
29.46 
±0.55 
62.77 
±0.88 
21.53 
±0.53 
45.51 
±0.25 
14.29 
±0.53 
28.83 
±0.24 
6  54.62 
±0.31 
100 
±0.17 
41.12 
±0.74 
87.67 
±0.23 
34.42 
±0.58 
73.12 
±0.43 
25.35 
±0.61 
52.58 
±0.27 
16.12 
±0.27 
34.23 
±0.27 
7  60.76 
±0.22    48.74 
±0.77 
95.41 
±0.17 
41.58 
±0.34 
82.77 
±0.56 
31.39 
±0.87 
64.79 
±0.51 
19.76 
±0.73 
42.58 
±0.31 
8  68.81 
±0.15    55.71 
±1.22 
100 
±0.08 
46.23 
±0.75 
91.56 
±0.55 
35.83 
±0.33 
72.58 
±0.42 
22.93 
±0.53 
51.87 
±0.42 
9  74.73 
±0.25    62.78 
±0.11    54.79 
±0.63 
97.43 
±0.34 
41.78 
±0.19 
80.44 
±0.87 
24.92 
±0.25 
57.48 
±0.43 
10  79.83 
±0.47    68.45 
±0.25    58.77 
±0.63 
100 
±0.55 
46.38 
±0.57 
86.46 
±0.44 
29.78 
±0.22 
68.33 
±0.47 
11  86.58 
±0.55    76.17 
±0.44    64.24 
±0.55    52.58 
±0.54 
95.76 
±0.27 
33.65 
±0.36 
73.44 
±0.63 
12  91.76 
±0.44    80.58 
±0.34    72.51 
±0.75    57.39 
±0.71 
100 
±0.16 
36.38 
±0.66 
80.44 
±0.14 
 
 
Effect of agitational intensity 
The effect of agitational speed on the in vitro release of ATN and AMB was studied and 
the data is recorded in Table 7. Release studies of the best formulation (F6) were carried 
out in dissolution apparatus USP-2 at three different speeds i.e. 50rpm, 100rpm and 
150rpm. Samples were withdrawn at predetermined intervals and analyzed by UV 
spectrophotometer. In vitro release was to found to follow the zero order release kinetics in 
all three cases determined by the PCP disso software. Release profile(s) at all three 
conditions were compared using one way ANOVA (Table 7). The calculated F value was 
found to be less than tabulated F value for both the drugs, thus suggesting that the 
variation in agitational intensity does not have any significant effect on release profiles of 
the asymmetric membrane tablets. This effect describes the fact that the in-vitro release 
from the AMCs is independent of the hydrodynamic conditions of the body [10]. 
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Fig. 11.  Effect of osmotic pressure on Amlodipine Besylate release 
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Tab. 7.  In-vitro release data for studying the effect of agitation intensity 
Time  
(hr) 
% Cumulative drug release 
50 rpm  100 rpm  150 rpm 
ATN  AMB  ATN  AMB  ATN  AMB 
0  0  0  0  0  0  0 
1  9.78±0.121  18.57±0.123  11.82±0.142  20.58±0.152  11.29±0.172  21.25±0.123 
2  18.52±0.132  34.29±0.132  20.56±0.147  36.58±0.157  18.23±0.162  35.28±0.142 
3  21.62±0.132  57.25±0.141  28.29±0.341  58.42±0.172  26.45±0.217  60.49±0.163 
4  31.57±0.142  80.27±0.162  37.45±0.231  82.93±0.163  34.69±0.160  85.92±0.173 
5  40.36±0.142  95.57±0.152  47.35±0.211  98.52±0.129  45.57±0.163  98.31±0.183 
6  46.72±0.135  100±0.0120  54.62±0.238  100±0.0110  48.85±0.182  100±0.018 
7  56.12±0.152    60.76±0.182    58.65±0.173   
8  60.24±0.141    68.81±0.178    65.86±0.172   
9  67.77±0.153    74.73±0.175    71.23±0.152   
10  73.98±0.152    79.83±0.163    78.47±0.183   
11  80.74±0.154    86.58±0.173    85.57±0.256   
12  87.36±0.172    91.76±0.193    90.5±0.162   
 
Effect of polymer diffusibility 
The effect of polymer diffusibility on drug release (since drug release results from diffusion 
of drug through asymmetric membrane barrier) from the best formulation (F6) was studied 
(Fig. 13& 14) using formulation that was stored in a dessicator for 24 h and also form a 
freshly fabricated drug delivery device. Polymer  diffusibility from freshly prepared 
formulation was calculated to be 4959.84 µm/min and 5251.60 µm/min for ATN and AMB, 
respectively, and polymer diffusibility for formulation stored in a dessicator for 24 h was 
calculated to be −9397.60 µm/min and −8927.72 µm/min for ATN and AMB, respectively. 
A positive value for polymer diffusibility for the freshly prepared formulation suggests a lag 
time in release of ATN and AMB, which means that the drug has not penetrated the 
membrane (i.e. the drugs are not released until the dissolution medium has penetrated the 
membrane barrier) dissolving the drug in the reservoir, whereas a negative value for 
polymer diffusibility for the formulation stored for 24 h suggests saturation of ATN and 
AMB at the pores of the AMC. Because of this saturation of the drug at the pores of the 
membrane, when the dissolution medium enters the AMC the process of drug entering into 
the solution form will be faster, thereby resulting in faster release from the system. 
Polymer diffusibility studies suggest that the stored formulations may result in burst 
release before achieving steady state and can be an important parameter in determination 
of the minimum effective concentration required by the drugs [11]. 
The current time of 24 h was preferred  based on our previous studies that the pore 
saturability for the asymmetric membrane capsules was attained within 24 h, and that the 
drug release profile from the formulations stored at 24 h or beyond were statistically 
similar. 
Since the previous studies [11] have shown that a burst release is achieved within the first 
hour of release due to the pore saturability, the study was conducted for the same.   Osmotically Regulated Two-Compartment Asymmetric Membrane Capsules for Simultaneous …  247 
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Moreover, it was expected that the two formations (after the initial burst from the stored 
formulation) will have a similar drug release. 
Tab. 8.  In-vitro release data for studying the effect of polymer diffusibility on ATN and 
AMB release 
S.No.  Time  
(min) 
% Cumulative drug release 
Freshly prepared formulation  Stored formulation 
ATN  AMB  ATN  AMB 
1.  0  0  0  0  0 
2.  10  1.45±0.110  2.12±0.115  5.19±0.113  9.46±0.135 
3.  20  2.12±0.114  4.35±0.117  7.42±0.115  18.87±0.144 
4.  30  2.89±0.118  8.22±0.171  9.37±0.212  23.58±0.121 
5.  40  5.12±0.121  14.24±0.129  11.36±0.141  27.89±0.110 
6.  50  6.87±0.151  20.67±0.153  13.11±0.143  31.34±0.171 
7.  60  8.79±0.119  26.34±0.211  14.78±0.311  35.43±.211 
 
In-vitro demonstration of effect of membrane thickness on dissolution fluid entering 
the AMC 
To demonstrate the effect of membrane thickness on dissolution fluid entering the AMC, 
the volume that enters in the capsules was determined. For the determination of volume, 
different osmotic pressures (65.55 atm, 182.08 atm, 327.74 atm, 455.19 atm, 546.23 atm, 
655.47 atm and 910.38 atm) were created in the external media by adding different 
amounts of osmotic agent (KCl). It was assumed that when the osmotic pressure inside 
the capsule and external media was equal (i.e. iso-osmotic) there will be no release of 
drugs. The osmotic pressure, at which the drug release was zero, was recorded for 
Atenolol and Amlodipine Besylate. The results showed that at 455.19 atm and 910.38 atm 
osmotic pressure Atenolol and Amlodipine Besylate release was found to be  zero, 
respectively. Therefore,  it was concluded that 455.19 atm and 910.38 atm osmotic 
pressure was developed inside the capsule’s body and cap,  respectively, which was 
equivalent to external media osmotic pressure. The volume that was responsible for 
building up osmotic pressure inside the capsule was calculated for both compartments. 
The results showed that 0.072 ml fluid entered into the body of AMC and 0.0072 ml fluid 
entered into the cap of AMC, because in the modified F6 formulation cap of AMC was 
prepared by 15% w/v coating solution (cellulose acetate solution in acetone and alcohol) to 
achieve prolonged release of Amlodipine Besylate. 
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Fig. 13.  Effect of polymer diffusibility on ATN release  
 
 
 
Fig. 14.  Effect of polymer diffusibility on AMB release  
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Tab. 9.  In-vitro release data for demonstration of effect of membrane thickness on 
dissolutionfluidentering the AMC 
S. 
No. 
Time 
(min.) 
% Cumulative drug release 
65.55 atm  182.08 atm  327.74 atm  455.19 atm 
ATN  AMB  ATN  AMB  ATN  AMB  ATN  AMB 
1.  0  0  0  0  0  0  0  0  0 
2.  30  0.69  1.17  0.56  0.87  0.34  0.65  0  0.4 
3.  60  1.56  2.58  1.29  2.05  0.72  1.21  0  0.78 
4.  90  2.43  3.7  2.09  3.28  1.06  1.71  0  1.07 
5.  120  3.39  5.18  2.89  4.23  1.41  2.31  0  1.55 
S. 
No. 
Time 
(min.) 
% Cumulative drug release     
546.23 atm  655.47 atm  910.38 atm     
ATN  AMB  ATN  AMB  ATN  AMB     
1.  0  0  0  0  0  0  0     
2.  30  0  0.35  0  0.25  0  0     
3.  60  0  0.64  0  0.52  0  0     
4.  90  0  0.96  0  0.79  0  0     
5.  120  0  1.31  0  1.04  0  0     
 
Stability studies 
The stability study was carried on with modified best formulation (F’6) according to ICH Q1 
A guidelines for three months to investigate the influence of humidity and temperature on 
appearance and in vitro drug release. The results (table 10) revealed that the formulation 
was stable when store in sealed as well as unsealed containers at 40°C ± 2.0 / 75% RH ± 
5 as. In terms of appearance the capsules texture and color remained unchanged, thus 
proving the stability of asymmetric membrane capsules. The capsules were also subjected 
to dissolution for determining the % drug release after 12 h and showed that formulations 
have comparable release profiles, thus suggesting that there was no problem of stability 
for asymmetric membrane tablets. 
Tab. 10.  Compiled data for stability testing of asymmetric membrane capsules of ATN 
and AMB 
Time interval  
(months) 
Parameters 
Appearance  Maximum % in-vitro release (after 12 h) 
ATN  AMB 
0  White & smooth  89.63  94.69 
1  White & smooth  89.56  94.47 
2  White & smooth  88.78  93.44 
3  White & smooth  88.59  93.27 
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